ATOS Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. (ATOS) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.92 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.1% since its last earnings release on August 7, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions.
Sector
Healthcare
Industry
Biotechnology